Skip to content
Screener

Bio-Techne TECH Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Revvity logo
RevvityRVTY
$48.82M-77.1%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$46.95M+18.8%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$4.61M+112%
GeneDx Holdings logo
GeneDx HoldingsWGS
-$63.57M-885%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO

Other financials

Income statement

See full
Revenue$311.4M-1.5%
Gross profit$208.3M-2.9%
Operating income$75.5M+95.0%
Net income$51.0M+126%
EPS (diluted)$0.32+129%

Balance sheet

See full
Cash & equivalents$209.8M+49.2%
Total debt$290.3M-31.4%
Total equity$2.1B+3.3%
Total assets$2.6B-3.5%

Cash flow

See full
Operating cash flow$86.7M+111%
CapEx$9.1M-10.2%
Free cash flow$77.6M+150%

Valuation

See full
Market cap$11.26B+43.3%
Enterprise value$11.34B+39.3%
P/E75.2×+16.9×
P/S9.3×+2.9×

Profitability

See full
Gross margin65%-0.8pp
Operating margin14.2%-7.9pp
Net margin10.9%-6.7pp
FCF margin22.3%+4.0pp

Returns & leverage

See full
Return on equity6.5%-3.9pp
Debt / equity0.1×-0.1×
Current ratio4.5×+0.8×

Where this comes from

Reported directly by Bio-Techne in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Bio-Techne’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:31 PM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056302
Line itemQuarter Ended / March 31, 2026Quarter Ended / March 31, 2025Nine Months Ended / March 31, 2026Nine Months Ended / March 31, 2025
Foreign currency translation income (loss)(4,352)5,311(4,440)1,049
Unrealized gains (losses) on derivative instruments(160)(1,713)(2,536)(4,785)
Other comprehensive income (loss)(4,512)3,598(6,976)(3,736)
Comprehensive income$46,535$26,186$120,265$87,342
Earnings per share:
Basic$0.33$0.14$0.82$0.58
Diluted$0.32$0.14$0.81$0.57
Weighted average common shares outstanding:

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Bio-Techne's comprehensive income (loss), net of tax, attributable to parent?
Bio-Techne (TECH) reported comprehensive income (loss), net of tax, attributable to parent of $46.54M in Q1 2026.
How has Bio-Techne's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Bio-Techne's comprehensive income (loss), net of tax, attributable to parent increased by 77.7% year-over-year, from $26.19M to $46.54M.
What is the long-term trend for Bio-Techne's comprehensive income (loss), net of tax, attributable to parent?
Over 3 years (2022 to 2025), Bio-Techne's comprehensive income (loss), net of tax, attributable to parent has grown at a -28.8% compound annual growth rate (CAGR), from $254.14M to $91.84M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric is the sum of net income and other comprehensive income, representing the total change in equity from all sources during the period. It offers a comprehensive view of the company's total financial performance including items that bypass the traditional income statement.

Ask your AI about Bio-Techne's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude